A novel device placed under the sternum outside of the heart and veins has the potential to deliver pacing and defibrillation therapy, according to a feasibility study presented at the Heart Rhythm Society’s annual scientific sessions.

A sensing filter added to Boston Scientific’s Emblem subcutaneous implantable cardioverter defibrillators (S-ICDs) more than halved the number of inappropriate shocks given to patients over a one-year period, according to a real-world European study presented May 11 at the Heart Rhythm Society’s annual scientific sessions in Boston.

The World Health Organization (WHO) is challenging all nations to rid their foods of artificial trans fats in the next five years, a move expected to curb the burden of cardiovascular disease worldwide. This task would likely require countries to use regulations or legislation to force food manufacturers to make the switch.

DUBLIN and BOSTON — May 11, 2018 — Medtronic plc (NYSE:MDT) today announced new clinical study results demonstrating that an investigational algorithm, utilizing the accelerometer signal in the Micra(TM) Transcatheter Pacing System (TPS) may restore AV synchrony, improving cardiac function in patients with sinus rhythm and atrioventricular (AV) block.

Atrial fibrillation (AFib) should never be considered fully cured, according to a recent study in The BMJ, because patients with this designation carry higher risks of stroke and death compared to people who have never had the arrhythmia.

Annual well woman exams, traditionally performed by an OB/GYN, provide a “golden opportunity” for women to get their heart health evaluated, according to a new joint advisory issued by the head officials of the American Heart Association (AHA) and the American College of Obstetricians and Gynecologists (ACOG).

Catheter ablation was found to be superior to optimal drug therapy for the primary treatment of atrial fibrillation (AFib) in the randomized CABANA trial presented May 10 at the Heart Rhythm Society’s annual scientific sessions in Boston. However, there was a caveat.

The American Heart Association/American Stroke Association (AHA/ASA), the Paul G. Allen Frontiers Group and other partners are devoting $43 million to fund a research initiative for better ways to prevent and treat age-related cognitive impairment.